Neurogene Valuation Multiples

Neurogene Overview

About Neurogene

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Founded

2018

HQ

Employees

107

Website

neurogene.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: —

Net Income: ($97M)

EV

$75M

Valuation Multiples

Multiples.vc

Start free trial

Neurogene Financials

Neurogene reported last 12-month revenue of —.

In the same LTM period, Neurogene generated had net loss of ($97M).

Neurogene P&L

In the most recent fiscal year, Neurogene reported revenue of — and EBITDA of ($87M).

Neurogene expects next 12-month revenue of XXX and NTM EBITDA of XXX

Neurogene Stock Performance

Neurogene has current market cap of $333M, and enterprise value of $75M.

Neurogene's stock price is $21.37.

Neurogene Valuation Multiples

Neurogene trades at (0.9x) EV/EBITDA.

Neurogene Financial Valuation Multiples

As of April 10, 2026, Neurogene has market cap of $333M and EV of $75M.

Equity research analysts estimate Neurogene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Neurogene has a P/E ratio of (3.4x).

Neurogene Margins & Growth Rates

Neurogene's revenue in the last fiscal year declined by (100%).

Neurogene's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.0M for the same period.

Neurogene Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Neurogene M&A Activity

Neurogene acquired XXX companies to date.

Last acquisition by Neurogene was on XXXXXXXX, XXXXX. Neurogene acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Neurogene Investment Activity

Neurogene invested in XXX companies to date.

Neurogene made its latest investment on XXXXXXXX, XXXXX. Neurogene invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).